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1. Introduction 
Both embryonic and somatic stem cells have attracted many scientists’ interest as they 
appear to be ideal candidates for cell therapy to treat various degenerative diseases and 
tissue injury for which there are no cures available. However, during the last few years, 
extensive amount of publications have focused on somatic cell reprogramming, a reversal of 
cell fate from a mature differentiated state to an undifferentiated state or directly to that of 
progenitors or mature cells of a different cell type. The advantage of that strategy is to 
obtain an autologous source of cells, which when differentiated and/or transplanted will 
not be rejected by the recipients. Several strategies have been applied for reprogramming 
purpose, including somatic cell nuclear transfer (SCNT), somatic-stem cell fusion, cell-free 
extract treatment and induced pluripotent stem cell (iPSC) generation. As a model for 
studying nuclear reprogramming, cell-cell fusion has been studied since the 1970’s. Recent 
observations demonstrate that transplanted stem cells can differentiate into multiple cell types 
in vivo and have brought investigators to a new stage for applying cell fusion to regenerative 
therapies, cherishing the idea that fusion-based reprogramming may possess more potential 
than the original belief. In this chapter, we have briefly discussed the current progress of 
somatic cell reprogramming induced by cell fusion. In our lab, using human embryonic stem 
cells (hESCs) and human fetal fibroblasts (HFFs) as fusion candidates, we have compared the 
fusion efficiency in vitro using different methods and successfully generated hybrid cells. 
Research publications to date suggest that cell fusion between stem cells and somatic cells may 
restore regenerative capacity of terminally differentiated cells and can be applied for 
transplantation and cell therapy. However, certain aspects of disadvantages cannot be 
neglected. The limitations of cell fusion based reprogramming includes the presence of stem 
cell nuclei in the hybrid cells, the possibility of causing immune-rejection and the genetic 
instability of hybrid cells. Insights of both pros and cons have been described in this chapter 
and we conclude that reprogramming induced by cell fusion can be achieved at different 
efficiencies when using various fusion methods in vitro. The hybrid cells show ESC-like 
properties with double nuclear content. More detailed studies will be needed to remove ESC 
nuclei before these cells can be used for clinical purposes. 
www.intechopen.com
 Methodological Advances in the Culture, Manipulation and  
Utilization of Embryonic Stem Cells for Basic and Practical Applications 
 
238 
2. Stem cells and regenerative medicine 
Stem cells have been identified as clonal cells that have the capacity to self-renew as well as 
the ability to generate more than one type of specialized cells (Weissman, 2000; Cowan and 
Melton, 2006; Sidhu and Ryan et al., 2010). These properties make them important in wound 
healing and in the processes of regeneration throughout life. Regenerative medicine is an 
emerging field with the aim of repairing tissue/organs caused by injury, disease or aging by 
restoring the function of cells, tissues and organs faster and better. The techniques being 
investigated and applied include manipulation of stem cell behaviour by genetic (gene 
therapy) or non-genetic means, followed by transplantation of stem cells (cell therapy) and 
in vitro-grown cells/tissues/organs taking the dynamics and microenvironment into 
account (tissue engineering). 
The traditional approach to reduce disability and improve health of patients has been organ 
transplantation, which started with the successful transplantation of the kidney between 
identical twins (Guild and Harrison et al., 1955). With the development and usage of 
immunosuppressant drugs, improved survival rate of patients have been reported 
(Chkhotua and Klein et al., 2003; Kim and Kwon et al., 2004) and solid organ types have 
expanded to the heart, liver, pancreas and lung (Hariharan and Johnson et al., 2000; Sayegh 
and Remuzzi, 2007). However, despite these positive aspects, there is shortage of 
transplantable organs. According to the official U.S. Government information on organ and 
tissue donation and transplantation (http://www.organdonor.gov/), by June 2010 more 
than 108,000 people are waiting for transplantation surgeries and this number continues to 
rise by approximately 300 people per month due to scarcity of available donors. 
Regenerative medicine is a broad phrase used to describe the field of medicine that covers a 
diverse range of research including cell therapy, tissue engineering and transplantation. The 
use of stem cells in regenerative medicine provides unlimited cell sources for clinical 
application that overcome the shortage of tissue/organs. There are three classes of stem cells 
according to their origin: embryonic, germinal and adult stem cells (also known as somatic 
stem cells). Depending on their capacity to differentiate into other cell types, stem cells may 
be classified into totipotential, pluripotential and multipotential stem cells (Rao and 
Mattson, 2001). Despite the fact that more and more research are showing evidence for the 
potential use of stem cells in regenerative medicine (Bajada and Mazakova et al., 2008), it is 
not clear which type of stem cell provides the best approach for cell therapy.  
2.1 Adult stem cells in regenerative medicine 
There are different types of adult stem cells, some of these include hematopoietic stem cells 
(HSCs), mesenchymal stem cells (MSCs), adipose tissue-derived stem cells (ADSCs), cardiac 
stem cells (CSCs), neural stem cells (NSCs), pancreatic stem cells (PSCs), hepatic oval cells 
(HOCs) and bronchioalveolar stem cells (BASCs). Adult stem cells are located within a stem 
cell niche and upon injury, proliferate to maintain the stable stem cell number and generate 
differentiated cells to replace damaged tissue cells. Adult stem cells have had applications in 
the treatment of many diseases including nervous system disorders, heart disorders, 
diabetes, muscular disorders, vascular disorders and interstitial lung diseases (Mimeault 
and Batra, 2008). An easy and straightforward approach for applying stem cells in 
regenerative medicine is to transplant/inject adult stem cells or differentiated cells into the 
targeted diseased or injured site, whereas the approach of tissue engineering is designed to 
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generate solid tissue or organ by using bioreactors, scaffolds and other biomaterials in vitro 
before transplantation. 
Bone marrow (BM) has long been known to contain at least three types of stem cells: HSCs, 
MSCs and endothelial progenitor cells (EPCs) (Alison and Islam, 2009). HSCs are able to 
reconstitute the hematopoietic system by differentiation into all types of blood cells and 
MSCs are able to differentiate into skeletal tissues (Bonnet, 2003). Currently, BM or BM-
derived stem cell transplantation is the best-known and well-established stem cell-based 
therapy in regenerative medicine. When HSCs are transplanted for either allogenic or 
autologous therapy, function of bone marrow that was damaged can be re-established 
through engraftment and continuous generation of a new hematopoietic system (Armitage, 
1994; Shizuru and Negrin et al., 2005). HSC transplantation method has been established and 
has become a standard therapy for the treatment of many hematopoietic diseases including 
Hodgkin’s and non-Hodgkin’s lymphoma, acute and chronic myelogenousleukemia and 
myelodysplastic syndromes (Armitage, 1994; Copelan, 2006). 
A concept that has brought much attention recently in the field of adult stem cell research is 
plasticity, which describes the phenomenon that restrictions in cell fates are flexible and the 
capacity of stem cells to differentiate into various cell types, including those not of their 
lineage of origin (Raff, 2003). Being the most extensively studied adult stem cells, HSCs have 
received much more attention as a result of recent transplantation studies, showing their 
plasticity to give rise to many non-hematopoietic cells both in vivo and in vitro (Quesenberry 
and Dooner et al., 2010). This will be discussed in further details in Section 3 of this chapter. 
2.1.1 Skeletal muscle 
Being the largest tissue in the body, skeletal muscle contains a population of stem cells 
known as satellite cells (SCs). SCs are normally quiescent but can be activated to 
proliferation upon injury or disruption of the basal lamina resulting in the generation of 
multinucleated myofibers for muscle regeneration (Shi and Garry, 2006). Many regulatory 
factors, including SC niche, stimulatory and inhibitory growth factors are involved in 
muscle regeneration. Allogenic SCs have been transplanted for therapeutic purposes. 
However, limited migration ability and poor survival of the injected cells have hampered 
their application in regenerative medicine (Broek and Grefte et al., 2010). Transgenic strategy 
to promote proliferation of SCs and derivation of other precursor cells involved in skeletal 
muscle regeneration have been investigated, showing great potential for the treatment of 
skeletal muscle injury and diseases. 
2.1.2 Heart 
The heart of human adults has been shown to contain resident adult stem cells with 
differentiation and regeneration capacity (Leri and Kajstura et al., 2005; Lyngbæk and 
Schneider et al., 2007). As precursors of cardiac muscle, transplantation of autologous 
myoblast cells and other cell types, for example, cardiomyocytes and BM-derived cells have 
also been suggested to be potential therapy for the treatment of myocardial dysfunction 
(Rubart and Field, 2006).  
Apart from cell therapy, scientists have been attempted to create three dimensional scaffolds 
and engineering heart tissue. A recent improvement in this aspect was the establishment of 
a bio-artificial heart with a perfusion-decellularized matrix obtained from real heart (Ott and 
Matthiesen et al., 2008).  
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2.1.3 Liver, kidney and pancreas 
Both whole liver and hepatocytes have been transplanted to treat various liver diseases. 
However, due to limited number of available liver and hepatocytes, stem cells (especially 
BM-derived stem cells) have been considered a valuable source for obtaining sufficient 
number of cells for transplantation. Yet, the existence or absence of a stem cell population in 
adult liver is still not clear. Studies on liver development suggested the presence of progenitors 
in fetal liver (Schmelzer and Zhang et al., 2007) and another side population (SP) cells have also 
been found to contribute to hematopoietic and epithelial lineages (Terrace and Hay et al., 2009), 
representing the existence of a second potential hepatic progenitor cells. 
The adult kidney consists at least 26 types of different cells with low proliferative potential. 
Thus, kidney is considered a highly terminally differentiated organ. However, the kidney 
has regenerative and repair potential upon injury. Much effort has been made in looking for 
renal stem/progenitor cells residing in the adult kidney. Renal epithelial stem cells have 
been reported to exist and SP cells have been isolated from adult kidneys (Iwatani and Ito et 
al., 2004; Benigni and Morigi et al., 2010). In addition, there has been controversy as to 
whether the adult pancreas contains stem cells. In normal adult pancreas, β-cells are known 
to renew at a low rate, but the mechanism of this cell renewal is not clear and has been 
suggested to be either replication of differentiated β-cells or neogenesis of pancreatic 
progenitor cells. The presence of pancreatic stem/progenitor cells has been proposed in the 
adult pancreatic exocrine, pancreatic duct and islets (Efrat, 2008). However, further 
characterization of these cells is essential and to date, whether there is a true renal and 
pancreatic stem cell population still remains elusive. 
In addition, BM-derived stem cells have been reported to transdifferentiate to repair kidney 
and to generate insulin producing cells (Efrat, 2008; Iwatani and Imai, 2010). 
2.1.4 Cartilage and Bone 
When damaged, bone repair occurs within a compressed time frame and in a precise 
location, whereas damaged cartilage has shown apparent lack of self-renewal. Current 
research on cell-based skeletal tissue regeneration focuses on identification of an ideal cell 
type for tissue repair. Bone has been found to contain stem cells as well as osteoprogenitor 
cells that produce bone and cartilage (Nuttall and Patton et al., 1998; Gronthos and 
Zannettino et al., 1999). At the same time, BM-derived MSCs have been widely investigated 
for their potential to differentiate into bone and cartilage tissue (Arinzeh, 2005).  
2.1.5 Nervous system 
It has been suggested that diseases of the nervous system including spinal cord injury and 
degenerative diseases can be treated or at least improved by replacing dysfunctional cells 
with new ones derived from NSCs. The existence of NSCs in the central nervous system 
(CNS) was supported by the fact that the CNS can regenerate neuronal axons, replenish lost 
neural cells as well as recovery of neuronal functions. More specifically, NSCs reside in the 
subventricular zone of the forebrain and the dentate gyrus of the hippocampus, where they 
consistently generate new neural cells (McKay, 1997; Temple, 2001). To repair the nervous 
system, scientists have applied two main methods：transplantation of stem cells and allow 
them to differentiate into neurons/glial cells in vivo or induce differentiation in vitro before 
transplantation; alternatively, growth factors that are involved in brain development have 
been used to stimulate stem cells within the brain to repair damage (Okano, 2006). NSCs 
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have been considered an important source of neurons for transplantation in treating 
Parkinson’s disease. Other adult stem cells, including BM-derived stem cells have also been 
shown to differentiate towards neuronal lineage and possess the potential to be used for the 
relief from Parkinson’s symptoms (Morizane and Li et al., 2008). 
The major advantage of using adult stem cells is that these cells can be autologous (isolated 
from the patients themselves), lessening the possibility of rejection by the immune system. 
However, it is difficult to isolate pure population of adult stem cells due to the extremely 
low numbers existing in the adult tissue of interest (approximately 1 in 10,000 cells) 
(Marshak and Gardner et al., 2001). Another problem that hinders research on adult stem 
cells has been maintaining and expanding long-term cultures of these cells in vitro. 
2.2 Pluripotent stem cells in regenerative medicine 
Embryonic stem cells (ESCs) derived from spare embryos can be cultured in large numbers 
on feeder layers or extracellular matrices in defined medium (Yu and Thomson, 2008). These 
cells are pluripotent in that they are able to form all three germ layers when directly and 
spontaneously differentiated. A number of cell types, including neural progenitors, 
dopaminergic (DA) neurons, insulin-producing cells, cardiomyocytes, endothelial cells, 
hematopoietic cells and many others, have been generated from ESCs (Choumerianou and 
Dimitriou et al., 2008; Sidhu, 2008). Yet, destruction of embryos to isolate human embryonic 
stem cells (hESCs) is considered a major ethical concern regarding the use of these cells. 
Another limitation is the allogenic resource of these cells, which may result in immune 
rejection when transplantation is carried out. New technologies such as somatic cell nuclear 
transfer (SCNT) and somatic cell reprogramming (cell fusion and induced pluripotent stem 
cell, iPCS generation) offer opportunities to overcome transplantation issues (Figure 1). 
However, SCNT technique raises other ethical issues regarding the use of human eggs while 
the latter is being investigated extensively. The past couple of years have witnessed the 
progress of reprogramming and re-differentiation of these reprogrammed cells, although 
research on reprogramming is still in its early stages and much more work needs to be done 
before somatic cell reprogramming can be used in clinical therapy. 
One of the most exciting report in reprogramming was the generation of iPSCs from 
terminally differentiated somatic cells by transduction of four transcription factors (OCT4, 
SOX2, KLF4 and c-MYC) into fibroblasts (Takahashi and Yamanaka, 2006; Takahashi and 
Tanabe et al., 2007). Later, it was shown that the four factors can be substituted with 
different combinations or with small molecules and a variety of somatic cells were 
successfully reprogrammed (Amabile and Meissner, 2009; Cox and Rizzino, 2010). The 
iPSCs closely resemble ESCs and are pluripotent (Robbins and Prasain et al., 2010). The 
approach of generating patient-specific and disease-specific iPSCs lines has already been 
achieved (Dimos and Rodolfa et al., 2008; Park and Arora et al., 2008; Ebert and Yu et al., 
2009; Lee and Papapetrou et al., 2009). The use of these cells could pave the way for 
regenerative medicine without immune response that limits allogenic cell therapy or the 
ethics with human embryos destruction when isolating hESCs. 
However, one of the most important questions in iPSC generation is to identify the starting 
cells amongst somatic tissue that give rise to iPSCs, and this remains elusive. In addition, 
although new techniques using non-integrating viruses, transient plasmid transfection or 
small molecules have been developed to avoid changes to the somatic cell genome, the results 
need to be further confirmed. Most recently, research revealed a gene expression signature in 
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iPSCs that is different from ESCs, suggesting that iPSCs are not identical to ESCs; rather, they 
could be a unique subtype of pluripotent cell (Chin and Mason et al., 2009). 
Another strategy being explored to induce reprogramming of differentiated cells is through 
fusion with pluripotent cells (Figure 1). Fusion of human fibroblasts with hESCs generates 
tetraploid hybrid cells with gene expression patterns, epigenetic status and differentiation 
ability characteristic of hESCs (Cowan and Atienza et al., 2005). A reprogramming study 
based on hESC claimed re-expression of enhanced green fluorescent protein (EGFP) in 
OCT4-EGFP knock-in ESC-derived myeloid precursor cells after cell fusion (Yu and 
Vodyanik et al., 2006). Most recently, it was reported that iPSCs generated from fibroblasts 
also possess the ability to reprogram other somatic cells after fusion (Sumer and Jones et al., 
2010). In the following sections of this chapter, we will discuss fusion between different cell 
types and prospect future challenges and application of fusion-based reprogramming in 
regenerative medicine. 
 
 
Fig. 1. Approaches to reprogram somatic cells and differentiation of the resulting 
pluripotent cells for regenerative medicine. 
3. Cell-cell fusion 
3.1 Cell fusion during development in vivo 
Cell-cell fusion is a process that occurs in a range of normal development and infection 
conditions in vivo. The beginning of a new life and the first step of development is the event 
of fusion between the sperm and the egg, known as fertilization. While sperm-egg fusion 
has been a subject of intense investigation, the mechanism and factors that are essential for 
cell fusion are still not clear. Knockout studies on mouse models have shown that CD9 on 
the egg plasma membrane is essential for fusion (Boucheix, 2000; Kaji and Oda et al., 2000; 
Miyado and Yamada et al., 2000). Later, a sperm-specific glycoprotein Izumo, which is only 
detectable after the acrosome reaction, was found to be required for sperm-egg fusion 
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(Inoue and Ikawa et al., 2005). Later, during normal development, the formation of syncytia, 
where multiple distinct nuclei exist, was observed in placenta, skeletal muscle and bone 
formation.  
Trophoblast cells of mammals are known to fuse with neighbouring cells to form the 
syncytiotrophoblast. These syncytiotrophoblasts are maintained by further fusion with 
cytotrophoblasts and they serve as a good candidate for transportation of nutrients and 
hormones across the maternal and fetal blood vessels (Huppertz and Frank et al., 1998; 
Pötgens and Schmitz et al., 2002). 
Skeletal muscle is composed of multinucleate muscle fibres, which are the products of 
multistep fusion process during development. Fusion starts with mononucleatemyoblasts 
fusing with each other to form nascent myotubes containing a small number of nuclei. This 
is then followed by additional fusion between the multinucleate myotubes and myoblasts, 
leading to the formation of large and mature myotubes (Horsley and Pavlath, 2004). At a 
later stage of development, SCs can fuse with muscle fibres for regeneration and 
maintenance of the skeletal muscle. The mechanism and regulation of myoblast fusion is 
reviewed in detail recently (Pavlath 2010). 
Another example of cell fusion that occurs in vivo in mammals is macrophage fusion, which 
results in the formation of multinucleate osteoclasts and giant cells (Vignery, 2000). During 
osteoclastogenesis, macrophages fuse with each other to form multinucleate osteoclasts in 
the bone, or giant cells in chronic inflammatory sites. As a result, macrophages increase in 
size and consequently endow them enhanced capacity of resorption, which is illustrated by 
the difference in gene expression patterns of mono-/multi-nucleated macrophages 
(Teitelbaum and Ross, 2003). This resoption capacity has been shown to be important for 
bone remodelling and failure in fusion induces thick and brittle bone formation in 
osteopetrosis. 
3.2 Cell-cell fusion in tissue regeneration 
It has been reported that different types of cells can fuse spontaneously when co-cultured in 
vitro (Weiss and Green, 1967; Ying and Nichols et al., 2002). More recently, cell fusion has 
also been suggested to be involved in transdifferentiation and tissue regeneration. 
Transdifferentiation is a concept describing the process of conversion of cells from a specific 
lineage to that not of their lineage of origin and has been demonstrated by the plasticity of 
adult stem cells. BM-derived HSCs and MSCs are the most extensively studied adult stem 
cells, which have also been considered to possess the most plasticity and can give rise to 
non-hematopoietic cells. After BM transplantation, cells carrying markers indicating their 
origin can be found in different tissues, including the liver, lung, pancreas and muscle 
(Quesenberry and Dooner et al., 2010). Some scientists proposed that this is the consequence 
of fusion between transplanted cells and local somatic/precursor cells, rather than real 
transdifferentiation.  
An early transplantation study aimed to treat a muscle defective disease, Duchenne 
muscular dystrophy (DMD), suggested that fusion occurred between implanted cells and 
host myoblasts/muscle fibres. Later, transplantation of BM-derived progenitors suggested 
possible fusion between the progenitors and myofibers and their contribution in muscle 
regeneration (Gibson and Karasinski et al., 1995; Ferrari and Cusella-De Angelis et al., 1998). 
In humans, it was shown that exogenous BM cells fused with myofibres in vitro after BM 
transplantation contributed to tissue repair (Gussoni and Bennett et al., 2002). Additional 
www.intechopen.com
 Methodological Advances in the Culture, Manipulation and  
Utilization of Embryonic Stem Cells for Basic and Practical Applications 
 
244 
data also showed that repair of muscle injury was not the result of HSC transdifferentiation, 
but was the consequence of fusion between transplanted HSCs and muscle fibres, further 
confirming the importance of cell fusion during tissue repair at the site of damage (Camargo 
and Green et al., 2003; Corbel and Lee et al., 2003). 
Results from two groups using a hepatic lethal murine models showed regain of normal 
liver function after BM transplantation. The newly generated hepatocytes express genes of 
both donor and host, indicating fusion of donor and host cells. Southern blot and 
karyotyping analysis further confirmed that the hepatocytes derived, arise from BM and 
somatic cell fusion and not by transdifferentiation of HSCs (Vassilopoulos and Wang et al., 
2003; Wang and Willenbring et al., 2003). Together with the studies of muscle repair, it is 
accepted that in a damaged tissue model, BM can fuse with somatic cells at the site of injury 
and regenerate organ function. 
It was then indicated that this transdifferentiation induced by cell fusion is injury-
independent and could occur under normal conditions. Analysis of female brains that had 
male BM transplantation, revealed the existence of tetraploid Purkinje neurons (XXXY), 
indicating fusion between HSCs and existing Purkinje neurons. Similarly, after 
transplantation of green fluorescent protein (GFP)-positive BM into lethally irradiated wild-
type mice, GFP-positive Purkinje-BM cell heterokaryons containing two nuclei were 
observed, suggesting fusion had occurred (Weimann and Charlton et al., 2003; Weimann 
and Johansson et al., 2003). BM-derived MSCs have also been transplanted into Niemann-
Pick mice. The transplanted MSCs were shown to fuse with Purkinje neurons and develop 
into functional neurons to promote brain function (Bae and Furuya et al., 2005). 
BM cell fusion was also investigated using transgenic mouse models carrying either Cre-
recombinase or LacZ reporter gene, which is under the control of LoxP-flanked stop cassette 
mediated by Cre recombination. Spontaneous fusion was observed in the brain, liver and 
heart of irradiated healthy mice (Alvarez-Dolado and Pardal et al., 2003). More recently, it 
was suggested that fusion between BM cells and Purkinje cells and the formation of 
heterokaryon occurs at a much higher efficiency upon tissue injury than under normal 
conditions (Johansson and Youssef et al., 2008). Then another group sought to address fusion 
under strictly physiological conditions using the Cre-LoxP system. They claimed absence of 
binucleated cell generation after BM transplantation and favour the idea that fusion between 
HSCs and Purkinje neurons is only a transient event and under non-invasive conditions, no 
stable heterokaryons are formed (Nern and Wolff et al., 2009). 
Other studies on BM transplantation suggested that cell fusion could also be the mechanism 
of tissue repair for heart (Nygren and Jovinge et al., 2004), kidney (Fang and Alison et al., 
2005) and intestinal epithelium (Rizvi and Swain et al., 2006). However, there are also 
studies reporting HSC plasticity with no cell fusion observations (Newsome and 
Johannessen et al., 2003; Bailey and Jiang et al., 2004; Harris and Herzog et al., 2004). 
While some may ask whether stem cells regenerate tissue by fusing with other cells or by 
transdifferentiation, it will be fair to say that cell fusion and transdifferentiation do not 
exclude each other. In transplantation and transdifferentiation studies mentioned above, 
each group used a different cell population, including whole BM cells, HSCs and MSCs 
isolated based on expression of different cell markers. The diversity thus makes it hard to 
compare the results and conclude. Transdifferentiation of BM cells have been shown in vitro; 
however, cell fusion does occur during tissue repair as well as in normal tissues although at 
a low frequency. It is most possible that the mechanism of plasticity involves both fusion 
and transdifferentiation. For one thing, upon fusion of BM cells with another cell type, the 
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latter may induce differentiation of BM cells; for another, fusion may result in transient 
hybrid cells with plasticity, which can differentiate into different cell types. Further research 
will be needed to provide more information on stem cell plasticity and tissue regeneration. 
3.3 Fusion-induced reprogramming 
3.3.1 Fusion between pluripotent and somatic cells 
It has long been known that under co-culturing system, different cell types can fuse together, 
although at rather low rates. Somatic cells were shown to fuse spontaneously with ESCs in 
vitro and were reprogrammed (Pells and Di Domenico et al., 2002). 
The pioneer study was designed to fuse pluripotent embryonic carcinoma cells (ECCs) with 
primary thymocytes with the resultant hybrid cells showing similarities to the parent ECCs 
in their multipotent differentiation abilities (Miller and Ruddle, 1976). This indicated that 
pluripotency was not lost by the introduction of a somatic cell; on the contrary, pluripotency 
prevailed the cell fate and overwhelmed the differentiation pathways.  
More recent research has shown that pluripotency can be re-established in somatic cells 
by fusion with ECCs, embryonic germ cells (EGCs) and ESCs, suggesting that these 
pluripotent cells possess the same or similar components that mediates reprogramming 
(Han and Sidhu, 2008). Compared to ECCs and EGCs, ESCs may represent a better source 
for this fusion-based reprogramming and have been paid much attention. The 
programming abilities of mouse ESCs (mESCs) were first illustrated by showing that 
mouse spleen cells obtained pluripotency after fusion with ESCs (Matveeva and Shilov et 
al., 1998). After fusion with mESCs, the Oct4 gene was reactivated 48 hours later in mouse 
lymphocytes, which suggest pluripotent properties of the hybrid cells. This was also 
testified by the hybrids’ contribution to all three germ layers as well as the epigenetic 
status as assessed by DNA methylation pattern of imprinted and non-imprinted genes 
(Tada and Takahama et al., 2001). Similar to mESCs, hESCs can also reprogram 
differentiated somatic cells to an embryonic state by fusion (Figure 2). This was first 
achieved by Eggan’s group in which hESCs were fused with human fibroblasts, resulting 
in tetraploid hybrid cells with gene expression patterns, epigenetic status and 
differentiation ability characteristic of hESCs (Cowan and Atienza et al., 2005). Another 
fusion-induced reprogramming based on hESCs claimed re-expression of EGFP in OCT4-
EGFP knock-in ESC-derived myeloid precursor cells after fusion and ESC-specific marker 
gene expression in the hybrid cells. Furthermore, pluripotency of the hybrids were 
demonstrated by the formation of three germ layers and extra-embryonic tissues (Yu and 
Vodyanik et al., 2006). These results provide an alternative pathway to SCNT and iPSCs 
generation for reprogramming somatic cells and especially for studying the mechanisms 
of nuclear reprogramming. 
Fusion between same or similar cells results in synkaryons or homokaryons (Figure 2). The 
former are single nucleated cells in which chromosome loss or re-sorting has occurred to 
homokaryons, an intermediate cell type in the process of synkaryon formation. Similarly, 
the cells formed by the fusion of different types of cells are either synkaryons or 
heterokaryons. Heterkaryons contain multiple nuclei and each nucleus remains separate 
and stable over time. Heterokaryon formation has been used as a tool to overcome 
chromosome loss and rearrangement after fusion and as a model to study the role of 
cytoplasmic factors on gene expressions. When nuclear fusion occurs, the fused nucleus 
initially contains chromosomal content of both fusion partners, but then chromosome loss or 
re-sorting leads to the formation of snykaryons. 
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Fig. 2. Fusion between same or different types of cells and the resulting cell types. 
3.3.2 Comparison of different fusion methods 
Reactivation of previously silenced genes in the somatic cells after fusion with another cell 
type was first reported in heterokaryons of muscle and amniotic cells, indicating plasticity 
of differentiated cells can be changed by fusion (Blau and Chiu et al., 1983). Subsequent 
studies fusing different cell types demonstrated that silenced genes in differentiated cell 
types can be reactivated after fusion and the differentiated state is not fixed. Instead, the 
differentiated state of cells can be reset and regulated in the heterokaryons (Yamanaka and 
Blau, 2010). In the case of somatic-stem cell fusion, reprogramming of somatic cells have 
been reported as mentioned in this chapter and shown in Figure 2. 
Three approaches have been developed and applied for fusion-induced reprogramming: 
electro-fusion, polyethylene glycol (PEG)-induced fusion and Sendai virus-induced fusion. 
Electro-fusion, which involves delivery of an electric pulse to the fusing cells, was 
developed in the 1980s. It allows the two types of cells in a low conductivity medium 
suspension, be brought into close contact by dielectrophoresis, which uses high frequency 
alternating current and aligns the cells in a chain. Then, the high voltage electrical field 
pulses applied brings about an abrupt change in the ionic conductivity and membrane 
permeability, which results in temporary reversible membrane breakdown, pore formation 
on the membranes and finally combining of the membranes. The cells are held in place 
transiently by an alternating voltage to allow fused membranes to mature and components 
of the cell cytoplasm to mix. A number of studies reported high fusion rate and 
reproducibility when using electro-fusion (Radomska and Eckhardt, 1995). Electro-fusion 
www.intechopen.com
Reprogramming Somatic Cells by Fusion with Embryonic Stem Cells:  
Present Status and Prospects in Regenerative Medicine   
 
247 
has been applied to induce fusion between mouse EGCs/ESCs and somatic cells for 
reprogramming (Tada and Tada et al., 1997; Tada and Takahama et al., 2001).  
PEG is a chemical that has long been used to induce cell-cell fusion (Ahkong and Howell et 
al., 1975). Several mechanisms were suggested on how PEG mediates cell fusion. Being a 
linear polymer of ethylene oxides and hydroxyl terminals, PEG has the ability of binding to 
water molecules and form compounds. It is now widely accepted that PEG aggregates cell 
membranes as well as dehydrating in the areas of contact (MacDonald, 1985). At the same 
time, PEG also promotes fusion via positive osmotic pressure that likely helps stabilize 
fusion intermediates (Lentz, 2007). Fusion experiments mediated by PEG between both 
mouse and human ESCs have demonstrated that 50% PEG can be applied to reprogram 
somatic cells although at a rather low efficiency (Cowan and Atienza et al., 2005; Do and 
Schöler, 2005). 
Sendai virus (Hemagglutinating Virus of Japan, HVJ) is a type of enveloped virus that can 
bind to cell surface receptors on the target membrane and fuse with cell plasma membrane 
at neutral pH with the mediation of viral envelope glycoproteins (Robert Blumenthal, 1991). 
Cell fusion induced by HVJ was first reported to induce fusion among tumor cells, resulting 
in the formation of giant polynuclear structures (Okada, 1962). Then, cell fusion between 
mouse and human was induced by virus in 1965 (Harris and Watkins et al., 1965). The HVJ-
Envelope (HVJ-E) is inactivated and purified HVJ, with only the cell membrane-fusing 
capability retained. When HVJ-E are added to the cells at a concentration of several hundred 
per cell, they are absorbed on the cell surface immediately by the receptor acetyl type sialic 
acid (at the terminal of sugar chains), which is recognized by haemagglutinin–
neuraminidase (HN) protein at 4°C. This leads to distortion of the cell membranes due to the 
penetration of an F protein of the envelope into the lipid layer of the cell membrane, which 
allows an inflow of ions. At this stage, the cell/HVJ-E complex is brought to a 37°C 
environment to induce temporary alteration of the cell membrane structure and cell fusion 
(Hoekstra and Klappe et al., 1985; Henis and Gutman, 1987; Loyter and Chejanovsky et al., 
1989; Düzgüneş and Shavnin, 1992). Because the genomic RNA of the Sendai virus has been 
inactivated, there is no potential infective or proliferative harm to the cells. 
However, the fusion efficiency of these methods in reprogramming has not been compared. 
It is in fact hard to compare the results from the above mentioned studies directly. First of 
all, in the reports of different groups, different somatic cell types and different ESC lines 
were used, which may affect fusion efficiency. Secondly, even for the same fusion approach, 
conditions applied by each group differ slightly. 
We modified protocols of electro-fusion, virus induced fusion and PEG-induced fusion to 
suit two hESC lines and a human fetal fibroblast (HFF) cell line that have not been used for 
fusion-based reprogramming with the aim of determining their effectiveness of 
reprogramming human somatic cells. The results indicated that by optimizing fusion 
methods, hybrid cells between hESCs and HFFs could be generated at different efficiencies. 
These hybrid cells formed stem cell-like colonies and expressed stem cell specific markers. 
To identify the two types of cells, an auto-fluorescent hESC line Envy and CMFDA- or 
SNARF-labelled cells (MEL1 and HFF10T, respectively) were used. An additional drug 
selection process was applied for hybrid selection, which enabled screening of stem cells 
that fused with puromycin-resistant HFFs (HFF10T). Envy cells contain a GFP sequence and 
the constitutive expression of GFP makes them easily visible and distinguishable from 
feeder HFFs (Costa and Dottori et al., 2005). MEL1 hESCs were labelled with CMFDA to 
express a similar level of fluorescence as Envy under the microscope and flow cytometry 
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conditions, whereas HFF10T cells were labelled fluorescent red with SNARF. As shown in 
Figure 3A, cells that were dual fluorescent represent the fused hybrid cells. After induced 
fusion of hESCs and puromycin-resistant HFFs, cells were cultured in normal hESC growth 
medium with puromycin supplemented from day 2 to 14 days post-fusion to screen for 
hybrid cells. Morphological changes during this period were assessed at different time 
points and shown in Figure 3B (day 5 and passage 2 day 7). Puromycin is toxic to wild type 
hESCs and the cell death was observed within 24 h. Only hESCs that had fused with  
 
 
Fig. 3. hESC-HFF fusion. (A) A typical example of hybrid generation induced by cell fusion. 
(B) Formation of hybrid colony after fusion between Envy and HFF10T induced by PEG. (C) 
RT-PCR analysis of gene expression. Lanes 1 to 6 were loaded with samples (1) Envy, (2) 
HFF10T, (3) hybrid P1, (4) hybrid P2, (5) hybrid P3 and (6) water. (D) Chromosome numbers 
in hESCs, HFFs and hybrid cells. (D) Analysis of DNA content in HFF10T cells and hybrids 
(Han, unpublished data). 
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HFF10T cells that bear the puromycin-resistant plasmid sequence can survive the antibiotic 
selection system. Stem cell-like colonies started to form on day 4 and after 2 weeks, the 
colonies can be manually dissected for sub-culture and they illustrated the compact, phase-
bright cell cluster feature of hESCs (Figure 3B).  
RT-PCR (Figure 3C) shows that through the culturing process, pluripotency markers such as 
OCT4, NANOG and SOX2 were expressed in the putative hybrids at a comparable level to 
that in the hESC control, indicating their ESC properties. In contrast, AFPM, a somatic cell 
marker, was strongly expressed in HFF10T cells but not in hESCs. In the hybrid cells at P1 
and P2, this AFPM expression was removed, most probably due to reprogramming. 
However, a weak expression of AFPM was observed from P3 hybrid cells, suggesting re-
differentiation. Primers that specifically amplify GFP sequence that was inserted into Envy 
cells’ DNA and the puromycin-resistant sequence of the plasmid (siSTRIK) that was 
transferred into HFF10T cells were used to examine the origin of the hybrid cells. 
DNA content analysis and chromosome number counting reflects the ploidity of the cells. 
As shown in Figure 3D and 3E, a normal human diploid cell has 46 chromosomes (44 
autosomes and 2 sex chromosomes), whereas in a typical hybrid cell generated from PEG 
induced fusion between Envy/MEL1 and HFF10T cell, 92 chromosomes were contained 
within a single nucleus. The DNA content of hybrids showed an obvious loss of S phase 
cells and a trend of increased DNA content.  
 
 
Fig. 4. Quantification of fusion efficiency by flow cytometry between Envy and HFF10T cells 
induced by different methods (Han, unpublished data). 
When flow cytometer was applied, as shown in Figure 4, the GFP positive Envy and the 
SNARF-labelled HFF populations are separate and distinct. The fusion products appeared 
as a dual fluorescing population with magnitudes that are approximately equal to those of 
the stained fusion partners. The fusion efficiencies of the three methods (electro-fusion, 
virus-induced fusion and PEG-induced fusion) were compared using two different hESC 
lines, Envy and MEL1. There were no considerable differences in fusion results between the 
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two cell lines (data not shown). However, when fusion strategies are considered, it was 
found that in electro-fusion, voltage applied for generating pores on the membranes of cells 
caused cell lysis and resulted in less survival of hybrid cells or generation of stem cell-like 
colonies. Furthermore, PEG 1500 was able to generate the highest number of colonies with 
typical stem cell characteristics despite its cytotoxicity and low percentage of double-stained 
hybrid cells (Figure 4). Sendai virus fusion was shown to have a moderate fusion ability as 
determined by hybrid generation efficiency and number of colony formation. In the study, it 
was concluded that fusion using PEG was still superior compared to other fusion methods 
used. Our results showed a fusion rate of 1.0 ± 1.2% and 1.2 ± 1.0 % for two different hESC 
lines (Envy and MEL1 respectively). When colony number was counted, only 0.0003 ± 
0.0001% of the cell population was observed to form stem cell-like colonies. This was not 
improved by optimization attempts which involved changing the PEG concentration or 
modifying the incubation time. Nor did the density of the cells in the PEG solution have any 
effect on the fusion rate. This could be because PEG mediated fusion is affected by many 
factors that are hard to normalize, such as the size and shape of the cell pellet and the speed 
and vigor with which PEG is stirred into the resuspended cell pellet (Radomska and 
Eckhardt, 1995). 
4. Prospects of cell fusion in future regenerative medicine 
After injury or under pathological conditions, stem cells can proliferate and differentiate in 
order to regenerate and repair damaged tissues. During regeneration process, adult stem 
cells normally differentiate to cells that reside in the damaged site. As discussed earlier, in 
the organs of muscle, brain and liver, cell fusion has been demonstrated during tissue 
regeneration, despite of controversial reports. Stem cells from the BM origin have been of 
particular interest because they have shown to migrate to alternative locations and 
contribute to functional cells. Transdifferentiation was postulated as the mechanism of 
generation of the differentiated cell types after HSC and MSC transplantation. However, the 
finding that HSCs and MSCs can fuse with other cell types in vivo indicated that cell fusion 
could be the mechanism to explain the low number of newly generated functional cells in 
tissue repair after injury. Currently, it is still not clear whether the improvement of organ 
function after damage was a result of fusion-mediated recovery or production of growth 
factors and cytokines of the residue stem cells. Furthermore, it is possible that fusion occurs 
in more organs than we know and at a higher frequency than we expected. In addition, the 
function of cell fusion may be more important than what we have known in the process of 
organ or tissue repair. 
In vitro cell fusion studies have shown that fusion between different cell types can change 
cell fate and gene expression profiles. Fusion reverses the differentiated state of mature cells 
towards a more immature or even embryonic-like state (Tada and Takahama et al., 2001; 
Cowan and Atienza et al., 2005). 
Despite successful reprogramming, the strategy of inducing reprogramming by cell fusion has 
been problematic in the following aspects. Firstly, although the somatic cell genome is 
reprogrammed, the existence of ESC or other pluripotent cell genome in the tetraploid hybrids 
is a technical hurdle for therapeutic application. When transplanted or injected into somatic 
donors, immune rejection caused by the ESC genome could happen at a high frequency. 
Secondly, after fusion of two cells, both heterokaryons and synkaryons can be formed. 
Chromosome loss or spitting a nucleus of a heterokaryon results in the formation of 
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synkaryons and chromosomal instability and genetic instability have been reported (Vasilkova 
and Kizilova et al., 2007; Nowak-Imialek and Kues et al., 2010). This needs to be taken into 
consideration when clinical transplantation is the aim of generating these hybrids. Thirdly, the 
efficiency of fusion induced reprogramming has been low. Since the first study reporting the 
success of reprogramming human somatic cells after fusion with hESCs, efforts have been 
made in order to increase reprogramming efficiency in the system. Over expression of certain 
transcription factors, such as Nanog and Sall4, as well as manipulation of histonemethylase 
Jhdm2a and methyltransferease G9a, have been claimed to significantly enhance the ability to 
generate reprogrammed hybrids from fusion (Silva and Chambers et al., 2006; Ma and Chiang 
et al., 2008; Wong and Gaspar-Maia et al., 2008). However, these approaches need to be further 
tested in different cell lines and cell types. Lastly, fusion induced reprogramming was 
evidenced by morphological changes, gene expressions and epigenetic states, yet only limited 
functional reprogramming has been demonstrated (Yu and Vodyanik et al., 2006). 
To fully explore the mechanisms of fusion induced reprogramming for cell therapy and 
regenerative medical application, there are important questions yet to be answered. For 
example, the subcellular location of reprogramming factors has always been a subject of 
interest. When the nucleus and the cytoplasm of mESCs were fused with neurosphere cells 
separately, only karyoplasts could reactivate Oct4 in the somatic genome (Do and Scholer, 
2004). A conflicting observation was made later by Strelchenko et al., showing that hybrid 
cells generated by fusion of human somatic cells with enucleated ESCs express pluripotency 
markers OCT4 and TRA-2-39 (Strelchenko and Kukharenko et al., 2006). Most recently, it 
was reported that hESC cytoplast fusion can only initiate but unable to complete 
reprogramming, indicating the importance of the ESC nucleus in fusion-induced 
reprogramming (Hasegawa and Zhang et al., 2010) (Figure 2). Another issue is the 
possibility of immune rejection caused by the existence of the allogenic genome in the 
hybrid cells when they are transplanted into the somatic donor. In this case, removal of the 
pluripotent genome would be necessary. However, this would be hindered if the major 
elements responsible for reprogramming within ESCs are in the nucleus. Although a 
remedial approach has been developed in the mouse by allowing enough time for ESC 
nucleus to reprogram the somatic genome before removing the ESC nucleus (Pralong and 
Mrozik et al., 2005), the reprogramming ability of those nuclei-removed ESCs needs to be 
confirmed and it is not known if this approach could also be applied to hESCs. Targeted 
elimination of ESC chromosomes from mouse somatic cell-ESC hybrids is introduced as an 
alternative method to expel the effect of ESC genome (Matsumura and Tada et al., 2007). It 
was also reported that human B-lymphocytes can be reprogrammed towards a multipotent 
state in transient heterokaryons before nuclear fusion (Pereira and Terranova et al., 2008). In 
that case, it may be possible to remove ESC genome after reprogramming has occurred 
although this needs further investigation. Finally, the lacking of effective approaches to 
monitor early reprogramming events and being unaware of the molecules that mediate 
reprogramming in the ESCs, makes it challenging to achieve efficient fusion and 
reprogramming. However, considering that cell fusion is technically simple and 
reprogramming occurs fast after fusion, it is widely accepted that it is an ideal way to 
investigate the regulatory mechanisms of reprogramming. For example, it was 
demonstrated by heterokaryoyic cell fusion between mESCs and human fibroblasts that 
activation-induced cytidinedeaminase (AID), a DNA demethylation enzyme, is required for 
reprogramming initiation (Bhutani and Brady et al., 2010). 
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5. Conclusion 
In vivo cell fusion is a tightly regulated process that occurs in normal development or under 
pathological conditions. There are indications that induced in vitro cell fusion could be 
potentially applied for regeneration when stem cells are fused with somatic cells. A better 
understanding of the process will enable us to use cell fusion as an approach for cell 
therapy. Fusion between ESCs and somatic cells is considered a way of reprogramming 
somatic cells, with the generation of pluripotent cells that can be further differentiated into 
desired cell types. Cell-cell fusion may be faster and more efficient than iPSC technique as 
hESCs provide all the necessary factors for reprogramming. However, enucleation of ESC 
nucleus must be achieved before the hybrid cells can be used clinically. In addition, cell 
fusion is a useful tool for studying the molecular mechanism that controls somatic cell 
reprogramming. 
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